(-)-AH 23848

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (-)-AH 23848
• 英文别名: [1R-[1α(Z),2β,5α]]-(-)-7-[5-[[(1,1'-biphenyl)-4-yl]methoxy]-2-(4-morpholinyl)-3-oxocyclopentyl]-4-heptenoic acid；(1α(Z),2β,5α)-(+/-)-7-(5-(((1,1'-biphenyl)-4-yl)methoxy)-2-(4-morpholinyl)-3-oxocyclopentyl)-4-heptenoic acid；(Z)-7-[(1R,2R,5S)-2-morpholin-4-yl-3-oxo-5-[(4-phenylphenyl)methoxy]cyclopentyl]hept-4-enoic acid
• 化学式: C₂₉H₃₅NO₅
• 分子量: 477.601
• InChiKey: IOFUFYLETVNNRF-OSAZKUMMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  35
• 可旋转键数：
  11
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  76.1
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  (Z)-7-[(1R,2R,3R,5S)-3-hydroxy-2-morpholin-4-yl-5-[(4-phenylphenyl)methoxy]cyclopentyl]hept-4-enoic acid 生成 (-)-AH 23848
  参考文献：
  名称：

  COLLINGTON, E. W.;HALLETT, P.;WALLIS, C. J.;BRADSHAW, J.;HAYES, N. F.

  摘要：

  DOI：

文献信息

• Resolution of racemic bicycloheptenones
  申请人：GLAXO GROUP LIMITED

  公开号：EP0074856A2

  公开（公告）日：1983-03-23

  A method is described of resolving a racemic bicycloheptenone of formula (1) (in which X is a hydrogen, chlorine or bromine atom) which comprises forming an a-hydroxysulphonic acid - chiral amine salt thereof of formula (2) (in which A is the chiral amine), separating the diastereomeric salts and regenerating the bicycloheptenone of formula (1) in optically active form from the separated salt. The resolved bicycloheptenones are useful in the stereospecific synthesis of prostanoids and other substituted cyclopentanones.

  描述了一种解析式（1）外消旋双环庚烯酮（其中 X 为氢、氯或溴原子）的方法，该方法包括形成式（2）a-羟基磺酸-手性胺盐（其中 A 为手性胺），分离非对映盐并从分离盐中再生出光学活性形式的式(1)双环庚烯酮。 解析出的双环庚烯酮可用于前列腺素和其他取代的环戊酮的立体特异性合成。
• Preparation of aminocyclopentanealkenoic acids
  申请人：GLAXO GROUP LIMITED

  公开号：EP0078668A1

  公开（公告）日：1983-05-11

  A process is described for the preparation of compounds of the formula (1) (and their salts and hydrates) in which: W is alkylene X is cis or trans-CH=CH-; Y is a saturated heterocyclic amino group having 5-8 ring members; and R2 is C3-6 alkenyl (optionally substituted), C1-12 alkyl, or substituted or unsubstituted phenylalkyl, thienylalkyl, furanylalkyl, biphenylalkyl or naphthylalkyl. The process comprises hydrolysing an ester of the acid (1).

  描述了一种制备式（1）化合物（及其盐和水合物）的工艺，其中 (及其盐类和水合物）的工艺，其中 W 是亚烷基 X 是顺式或反式-CH=CH-； Y 是具有 5-8 个环成员的饱和杂环氨基；以及 R2 是 C3-6 烯基（任选取代）、C1-12 烷基或取代或未取代的苯基烷基、噻吩基烷基、呋喃基烷基、联苯基烷基或萘基烷基。 该工艺包括水解酸 (1) 的酯。
• Aminocyclopentane esters and their preparation and pharmaceutical formulation
  申请人：GLAXO GROUP LIMITED

  公开号：EP0074861A1

  公开（公告）日：1983-03-23

  Compounds are described of the formulae in which -COR1 is a complex ester or thioester group, W is alkylene, X is cis or trans -CH=CH or -CH2CH2-, n is 1 or 2, Y is a saturated heterocyclic amino group having 5 - 8 ring members, and R2 is unsubstituted or substituted phenylalkyl, thienylalkyl, naphthylalkyl or cinnamyl, and their salts and solvates. These compounds inhibit blood platelet aggregation and bronchoconstriction and may be formulated for use as antithrombotic and antiasthmatic agents.

  所述化合物的式中 -COR1 是复合酯或硫酯基团，W 是亚烷基，X 是顺式或反式 -CH=CH 或 -CH2CH2-，n 是 1 或 2，Y 是具有 5 - 8 个环成员的饱和杂环氨基基团，R2 是未取代或取代的苯基烷基、噻吩基烷基、萘基烷基或肉桂基，以及它们的盐和溶液。 这些化合物可抑制血小板聚集和支气管收缩，可配制成抗血栓和平喘剂。
• Method for the improvement of cyclosporine therapy
  申请人：MERCK FROSST CANADA INC.

  公开号：EP0300675A2

  公开（公告）日：1989-01-25

  The present invention relates to a method for improving cyclosporine therapy, in particular a method for limiting cyclosporine induced nephrotoxicity which comprises the adjunct administration in a mammal of an effective amount of cyclosporine and an effective amount of an antithromboxane A₂ agent.

  本发明涉及一种改善环孢素治疗的方法，特别是一种限制环孢素诱导的肾毒性的方法，该方法包括在哺乳动物体内辅助施用有效量的环孢素和有效量的抗黄体生成素 A₂剂。
• Use of thromboxane A2 antagonists for the manufacture of a medicament for improving post-ischemic myocardial dysfunction
  申请人：E.R. Squibb & Sons, Inc.

  公开号：EP0309801A2

  公开（公告）日：1989-04-05

  A method is provided for improving post-ischemic myocardial dysfunction such as contractile dysfunction or reperfusion injury by administering a thromboxane A₂ antagonist before, during or immediately after an ischemic attack.

  本研究提供了一种方法，通过在缺血发作前、发作期间或发作后立即使用血栓素 A₂拮抗剂，改善缺血后心肌功能障碍，如收缩功能障碍或再灌注损伤。